Werewolf Therapeutics, Inc. (HOWL)

Over the past six months, Werewolf Therapeutics, Inc.'s stock price has been impacted by several events. The company reported a decline in cash and cash equivalents in Q3 2025, leading to concerns about funding operations. The company experienced four analyst downgrades. WTX-124 received Fast Track status, and the company presented data expanding its PREDATOR® platform. Director Luke Evnin sold shares, and Werewolf Therapeutics received a deficiency letter from Nasdaq regarding its minimum bid price.

As a clinical-stage biopharmaceutical company, Werewolf Therapeutics, Inc. is primarily engaged in the costly development of drug candidates rather than commercial product sales. Consequently, the company currently generates no revenue from commercialized products, and therefore, traditional demand seasonality for products and services is not applicable.

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system for cancer and other immune-mediated conditions. The company utilizes its PREDATOR platform to engineer conditionally activated molecules, INDUKINE™ and INDUCER™ molecules, designed to selectively activate within the tumor microenvironment. Its lead product candidates include WTX-124, WTX-330 and JZP898, WTX-921, WTX-712 and WTX-518.

Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States.

In the past year, Werewolf Therapeutics' brand reputation has seen mixed signals. MarketBeat ranked the company 428th out of 872 stocks in the medical sector. The consensus rating from analysts is "Hold," with an average rating score of 2.25. The company's stock has underperformed both the US Biotechs industry and the broader US Market. A negative outlook has been attributed to weakening revenue and increased costs. Key risks impacting its reputation include a total dependence on its unproven PREDATOR platform and significant manufacturing challenges associated with its novel INDUKINE molecules.

Werewolf Therapeutics, Inc. has 85 institutional owners and shareholders who collectively hold 21,511,345 shares. Major institutional shareholders include Ra Capital Management, L.p., Mpm Asset Management Llc, MPM Oncology Impact Management LP, Bank Of America Corp /de/, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Sphera Funds Management Ltd., DC Funds, LP, Renaissance Technologies Llc, and PFM Health Sciences, LP. Institutional investors hold approximately 0.02% of the company's stock, insiders hold 42.22%, and retail investors hold 51.95%. Peter Kolchinsky owns the most shares.